



CooperVision Canada launches MyDay® MiSight® 1 day: Its Latest Contact Lens for Myopia Control

*Innovation Combines Advanced Silicone Hydrogel Material with
Proven ActivControl® Technology**

Rochester, NY, August 3, 2026 — CooperVision Canada today announced the launch of MyDay® MiSight® 1 day contact lenses, its latest innovation with ActivControl® Technology designed to slow the worsening of myopia in children.^{†2,3} The new product combines the advanced silicone hydrogel material of MyDay® lenses with the proven ActivControl® Technology found in original MiSight® 1 day lenses.^{*1}

Enrique Contreras, Country Manager at CooperVision Canada, explained the significance of the launch: "One in two children born today could have myopia by the age of 20.⁴ As a parent, I truly understand how myopia can significantly impact their quality of life, making it harder to participate in school, sports and other activities.^{5,6} Myopia can worsen rapidly, especially in younger children. That's why early intervention matters so much.⁷ Our commitment to tackling myopia continues to be unwavering. With MyDay® MiSight® 1 day, we've brought together the advanced silicone hydrogel material found in our MyDay® contact lenses with the life-changing potential of myopia control."^{*1}

The company's ActivControl® Technology has been shown to cut the worsening of myopia by approximately 50% and is backed by the longest-running soft contact lens clinical trial among children.^{†2,3} More than a quarter of a million children worldwide now wear contact lenses featuring this technology.⁸ The lens design incorporates vision correction zones and treatment zones to provide clear vision while helping to control the worsening of myopia.^{†1,3,9}

The new product offers better comfort and handling features compared with original MiSight® 1 day:^{§9}

- Preferred for comfort compared to the original MiSight® 1 day^{§9}
- Up to four times the oxygen transmissibility of a hydrogel one-day lens[†]
- Built-in UV blocker^{**}
- Rated easier to insert compared to the original MiSight® 1 day.⁹

Nathalie Trottier, Senior Manager, Professional Affairs at CooperVision Canada, added: "This innovation delivers 'always-on' myopia control—children benefit from treatment throughout the day, simply by wearing their contact lenses.^{††3,9,10} It's also designed to help support a smooth transition from myopia management to adult lens wear, thanks to its shared material and specifications with MyDay® lenses."^{††}

To support eye care professionals, CooperVision offers a suite of business tools including OptiExpert™, the Axial Length Estimator and QuickStart program—all available at no cost. In-practice marketing materials are also available on request.^{§§9}

MyDay® MiSight® 1 day will be available from Monday, August 3, 2026. Canadian eye care professionals can order both trial and revenue lenses through their usual CooperVision channels. At launch, the product will be available in the following parameters:

Sphere Power Range	Step Size
-0.25 to -6.00	0.25D
-6.50 to -10.00	0.50D

To learn more about CooperVision's evidence-based myopia management portfolio, visit: coopervision.ca/practitioner/myopia-management or contact your CooperVision representative.

#

Indications and Important Safety Information. Rx only. Results may vary.

ATTENTION: Reference the Package Insert or visit coopervision.ca/safety-myday-misight for a complete listing of Indications and Important Safety Information.

INDICATIONS: The MyDay MiSight 1 day (stenfilcon A) Soft Contact Lenses for Myopia Control are indicated for the correction of ametropia (myopia and hyperopia) in aphakic and non-aphakic persons with non-diseased eyes in powers from -20.00D to +2.00 diopters. The lenses may be worn by persons who exhibit astigmatism of -2.00 diopters or less that does not interfere with visual acuity. MyDay MiSight 1 day (stenfilcon A) Soft Contact Lenses for Myopia Control may reduce the rate of myopia progression in children (6-18) and correct ametropia. Reduction of myopia progression was observed in children with wearing time of 12 hours (8-16 hours) per day, 6.4 days (5-7) per week in a clinical study of MiSight 1 day (omafilcon A) containing identical dual focus optics to that of MyDay MiSight 1 day (stenfilcon A). Permanent myopia control after lens treatment is discontinued is not supported by clinical studies. MyDay MiSight 1 day (stenfilcon A) Soft Contact Lenses for Myopia Control are indicated for single use daily disposable wear. When prescribed for daily disposable wear, the lens is to be discarded after each removal.

* Proven to slow myopia progression in children compared to a single vision 1-day lens over a 3-year period

†Using measured and modeled data, pooled across ages (8-17), myopia progression was slowed by an average of approximately 50% with MiSight® 1 day, which shares the same ActivControl® Technology with MyDay® MiSight® 1 day

‡ MyDay® MiSight® 1 day contact lenses use the same ActivControl® Technology as the original MiSight® 1 day

§ 19% vs. 3% after 1 week of daily wear, $p=0.02$

◇ 94% vs. 81% after 1 week of daily wear, $p=NS$

¶ Based on manufacturers published data. MyDay® MiSight® 1 day has Dk/t of 100. Compared to the original MiSight 1 day (Dk/t 28), NaturalVue Multifocal 1 Day (Dk/t 25)

**** WARNING:** UV-absorbing contact lenses are NOT substitutes for protective UV-absorbing eyewear such as UV-absorbing goggles or sunglasses because they do not completely cover the eye and surrounding area. Persons should continue to use their protective UV-absorbing eyewear as directed. †† In clinical study, mean weekday wear time increased from 12.8 hours/day at 6-months to 13.9 hours/day at 6-years with a mean of >6.5 days/week for MiSight® 1 day, which shares the same ActivControl® Technology with MyDay® MiSight® 1 day

‡‡ MyDay® daily disposable and MyDay Energys®

§§ OptiExpert™ is an educational, reference and information tool for eye care professionals who may choose to use the app in connection with their own patient evaluation but it is not intended to be relied upon for clinical decision-making. OptiExpert™ is not intended as and does not constitute medical or optometric advice, nor is it intended to replace the patient evaluation performed by an eye care professional.

◇◇ Information on market promotions can be requested from your CooperVision Business Partner

1. Chamberlain P et al A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia Control. OVS 2019;96:556-567.
2. Arumugam B et al. Modelling Age Effects of Myopia Progression for the MiSight 1 day Clinical Trial. IOVS 2021;62(8):2333
3. CVI data on file, 2025
4. Holden BA, Fricke TR, Wilson DA, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036-1042
5. Lamoureux E et al. Myopia and Quality of Life: The Singapore Malay Eye Study (SiMES). IOVS 2008;49(13):4469
6. Chua S.Y.L., Foster P.J. (2020) The Economic and Societal Impact of Myopia and High Myopia:53-63. In: Ang M., Wong T. (eds) Updates on Myopia. Springer, Singapore
7. K. Zadnik et al. Factors Associated with Rapid Myopia Progression in School-aged Children. IOVS 2004;45(13):2306.
8. CVI data on file 2026. Internal global wearer modeling estimates for the 12-month period of March 2025 to February 2026.
9. CVI data on file, 2025. Prospective, 1-week, double masked, bilateral study with MiSight 1 day silicone hydrogel. N=32 subjects aged 8-18 years

10. Woods J et al. Ocular health of children wearing daily disposable contact lenses over a 6-year period. CLAE 2021 Aug;44(4):101391

About CooperVision

CooperVision, a division of CooperCompanies (Nasdaq: COO), is a global leader in contact lens innovation, dedicated to advancing vision at every stage of life. The company offers one of the industry's most comprehensive portfolios of soft and specialty contact lenses—including daily disposable, two-week and monthly options—with high-performance materials and optics across spherical, toric, and multifocal designs. With a strong heritage of addressing complex vision challenges such as childhood myopia, astigmatism, presbyopia, and irregular corneas, CooperVision combines purposeful research and development, state-of-the-art manufacturing, and deep practitioner partnerships to deliver clinically advanced solutions. Decades of experience and insight continue to shape the eye care profession and create meaningful advantages for both practitioners and wearers. For more information, visit www.coopervision.com.

About CooperCompanies

CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women's healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, Calif., CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com.

Media Contact

Laura DiCaprio, APR

McDougall Communications for CooperVision

laura@mcdougallpr.com or +1-585-434-2148